| Phasic dopaminergic transmission increases NO efflux in the rat dorsal striatum via a neuronal NOS and a dopamine D1/5 receptor-dependent mechanism S Sammut, A Dec, D Mitchell, J Linardakis, M Ortiguela, AR West Neuropsychopharmacology 31 (3), 493-505, 2006 | 111 | 2006 |
| Cocaine-and amphetamine-regulated transcript (CART) peptides modulate the locomotor and motivational properties of psychostimulants PR Couceyro, C Evans, A McKinzie, D Mitchell, M Dube, L Hagshenas, ... Journal of Pharmacology and Experimental Therapeutics 315 (3), 1091-1100, 2005 | 70 | 2005 |
| Bimodal, reciprocal regulation of fibroblast growth factor receptor 1 promoter activity by BTEB1/KLF9 during myogenesis DL Mitchell, JX DiMario Molecular biology of the cell 21 (15), 2780-2787, 2010 | 27 | 2010 |
| Platinum‐based regimens versus cetuximab in definitive chemoradiation for human papillomavirus‐unrelated head and neck cancer TH Beckham, C Barney, E Healy, AR Wolfe, A Branstetter, A Yaney, ... International journal of cancer 147 (1), 107-115, 2020 | 21 | 2020 |
| Evaluation of progress toward gender equity among departmental chairs in academic medicine BC Odei, P Gawu, S Bae, D Fabian, J Odei, C Lee, D Mitchell JAMA Internal Medicine 181 (4), 548-550, 2021 | 20 | 2021 |
| Evaluation of equitable racial and ethnic representation among departmental chairs in academic medicine, 1980-2019 BC Odei, R Jagsi, DA Diaz, D Addison, A Arnett, JB Odei, D Mitchell JAMA Network Open 4 (5), e2110726-e2110726, 2021 | 16 | 2021 |
| Contemporary utilization patterns and outcomes of thrombolytic administration for ischemic stroke among patients with cancer J Owusu-Guha, A Guha, PE Miller, S Pawar, AK Dey, T Ahmad, H Attar, ... International Journal of Stroke 16 (2), 150-162, 2021 | 14 | 2021 |
| AP-2α suppresses skeletal myoblast proliferation and represses fibroblast growth factor receptor 1 promoter activity DL Mitchell, JX DiMario Experimental cell research 316 (2), 194-202, 2010 | 14 | 2010 |
| Incidental prostate cancer diagnosed at radical cystoprostatectomy for bladder cancer: disease-specific outcomes and survival JB Kaelberer, MA O'Donnell, DL Mitchell, AN Snow, SL Mott, JM Buatti, ... Prostate international 4 (3), 107-112, 2016 | 12 | 2016 |
| Where are the women in radiation oncology? A cross-sectional multi-specialty comparative analysis B Odei, J Kahn, EB Holliday, DA Diaz, E Bello-Pardo, J Odei, J Bae, ... Advances in Radiation Oncology 6 (5), 100735, 2021 | 11 | 2021 |
| Identification of clinical and socioeconomic predictors of adjuvant therapy after trans-oral robotic surgery in patients with oropharyngeal squamous cell carcinoma S Baliga, B Klamer, S Jhawar, M Gamez, D Mitchell, A Blakaj, J Grecula, ... Cancers 12 (9), 2474, 2020 | 9 | 2020 |
| Is more always better? An assessment of the impact of lymph node yield on outcome for clinically localized prostate cancer with low/intermediate risk pathology (pT2-3a/pN0 … SN Seyedin, DL Mitchell, SL Mott, JK Russo, CR Tracy, AN Snow, ... Pathology & Oncology Research 25, 209-215, 2019 | 9 | 2019 |
| Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma CL Barney, S Walston, P Zamora, EH Healy, N Nolan, VM Diavolitsis, ... Oral Oncology 79, 9-14, 2018 | 9 | 2018 |
| Individualization of adjuvant therapy after radical prostatectomy for clinically localized prostate cancer: current status and future directions DL Mitchell, CR Tracy, JM Buatti, MC Smith, AN Snow, MD Henry, ... Clinical genitourinary cancer 14 (1), 12-21, 2016 | 8 | 2016 |
| Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer SR Jhawar, SJ Wang, A Thandoni, PK Bommareddy, JH Newman, ... Journal for immunotherapy of cancer 11 (7), 2023 | 6 | 2023 |
| Use of cetuximab added to weekly chemotherapy to improve progression-free survival in patients with recurrent metastatic head and neck squamous cell carcinoma after progression … M Issa, B Klamer, V Karivedu, P Bhateja, GI Laliotis, K Dibs, N Mladkova, ... Journal of Clinical Oncology 39 (15_suppl), 6038-6038, 2021 | 6 | 2021 |
| A predictive survival model for patients with head and neck squamous cell carcinoma treated with immune check point inhibitors M Bonomi, P Bhateja, M Issa, B Klamer, X Pan, A Blakaj, V Karivedu, ... Oral oncology 110, 104900, 2020 | 6 | 2020 |
| Primary vs nodal site PET/CT response as a prognostic marker in oropharyngeal squamous cell carcinoma treated with intensity‐modulated radiation therapy JM Eckstein, N Nolan, E Healy, CL Wright, A Jain, CL Barney, ... Head & neck 42 (9), 2405-2413, 2020 | 6 | 2020 |
| Disparities in survival outcomes among Racial/Ethnic minorities with head and neck squamous cell cancer in the united states S Baliga, VO Yildiz, J Bazan, JD Palmer, SR Jhawar, DJ Konieczkowski, ... Cancers 15 (6), 1781, 2023 | 5 | 2023 |
| Diversity in modern heart failure trials: Where are we, and where are we going U Anaba, A Ishola, A Alabre, A Bui, M Prince, H Okafor, O Kola-Kehinde, ... International journal of cardiology, 2021 | 5 | 2021 |
Dukagjin M. BlakajFaculty The Ohio State UniversityVerified email at osu.edu
